Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer Effects on Vascular Function in Chronic Kidney Disease
2023-503941-69-00Phase 2Completed
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Jul 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and hyperkalemia comparing Patiromer (Veltassa) with Placebo (2 arms). Primary endpoint: Change in indicators of arterial stiffness. Started Jul 2024; status: completed.
02
Drugs
patiromer
03
Conditions
chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on 2023-503941-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503941-69-00.